Europe Approves CAR T-Cell Therapy Tisagenlecleucel (Kymriah)

The European Commission has approved tisagenlecleucel (Kymriah, Novartis), which uses a patient’s own T cells to fight cancer, for two hematologic cancer indications, the company announced today. Tisagenlecleucel is an autologous, immunocellular cancer … (본문 전체 8/28/2018 3:15 AM)

1 thought on “Europe Approves CAR T-Cell Therapy Tisagenlecleucel (Kymriah)”

  1. I’ve been searching for hours on this topic and finally found your post. casino online, I have read your post and I am very impressed. We prefer your opinion and will visit this site frequently to refer to your opinion. When would you like to visit my site?

Leave a Comment